Larimar Therapeutics (LRMR) Cash & Current Investments (2013 - 2025)
Larimar Therapeutics (LRMR) posted Cash & Current Investments of $136.9 million for Q4 2025, down 21.99% on a QoQ basis from $175.4 million in Q3 2025, and down 25.4% year-over-year from $183.5 million in Q4 2024.
Larimar Therapeutics (LRMR) Cash & Current Investments (2013 - 2025) Analysis & Trends
Larimar Therapeutics' Cash & Current Investments history runs 13 years deep, the most recent figure standing at $136.9 million for Q4 2025.
- Quarterly Cash & Current Investments fell 25.4% year-over-year to $136.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $136.9 million (down 25.4% YoY) and the FY2025 annual result came in at $136.9 million, down 25.4% from the prior year.
- Cash & Current Investments was $136.9 million for Q4 2025 at Larimar Therapeutics, down from $175.4 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $227.3 million in Q1 2024 and bottomed at $54.9 million in Q2 2022.
- A 5-year average of $125.7 million and a median of $115.0 million in 2022 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2024 — Cash & Current Investments soared 116.95% — and 2025, when it sank 38.72%.
- Larimar Therapeutics' Cash & Current Investments stood at $70.1 million in 2021, then jumped by 68.95% to $118.4 million in 2022, then retreated by 26.71% to $86.8 million in 2023, then surged by 111.38% to $183.5 million in 2024, then retreated by 25.4% to $136.9 million in 2025.
- Business Quant data shows LRMR's Cash & Current Investments at $136.9 million in Q4 2025, $175.4 million in Q3 2025, and $138.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Larimar Therapeutics | 37.00 Mn | -99.85 Mn | - | 136.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 136.85 Mn |
| Sep 30, 2025 | 175.44 Mn |
| Jun 30, 2025 | 138.52 Mn |
| Mar 31, 2025 | 157.53 Mn |
| Dec 31, 2024 | 183.45 Mn |
| Sep 30, 2024 | 203.71 Mn |
| Jun 30, 2024 | 226.06 Mn |
| Mar 31, 2024 | 227.30 Mn |
| Dec 31, 2023 | 86.79 Mn |
| Sep 30, 2023 | 95.59 Mn |
| Jun 30, 2023 | 104.20 Mn |
| Mar 31, 2023 | 111.50 Mn |
| Dec 31, 2022 | 118.43 Mn |
| Sep 30, 2022 | 124.70 Mn |
| Jun 30, 2022 | 54.92 Mn |
| Mar 31, 2022 | 62.60 Mn |
| Dec 31, 2021 | 70.10 Mn |
| Sep 30, 2021 | 84.50 Mn |
| Jun 30, 2021 | 70.60 Mn |
| Mar 31, 2021 | 81.44 Mn |